Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares. The filing covers the month of September 2025, specifically detailing share repurchases executed on September 11, 2025. The Company is a foreign private issuer reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than comprehensive financial results (revenue, profit, or cash flow are not provided in this document).
- Transaction Date: September 11, 2025
- Shares Purchased: 205,355 ordinary shares of 31½ pence each
- Price Range: Lowest price paid was 1,494.50p; Highest price paid was 1,518.50p
- Volume-Weighted Average Price (VWAP): 1,509.04p
- Trading Venue: London Stock Exchange (XLON)
- Broker: Merrill Lynch International
- Treasury Share Holdings: Following this purchase, the Company holds 246,571,945 ordinary shares in treasury.
- Shares in Issue: 4,068,829,782 ordinary shares (excluding Treasury shares).
- Treasury Voting Rights: 6.06% of total voting rights.
Material Changes and Program Status
This purchase is part of the Company's existing buyback programme, executed pursuant to a non-discretionary agreement entered into with Merrill Lynch International on June 4, 2025. Since the inception of this agreement on June 4, 2025, the Company has purchased a total of 28,437,562 ordinary shares. The purchased shares are held as Treasury shares.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK cautions that any projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the Company's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No specific financial guidance or management commentary regarding operational outlook is provided in this specific filing.
Important Facts for Investor Verification
- Verify the total cumulative buyback volume since June 4, 2025 (28,437,562 shares) against the Company's authorized buyback limits.
- Confirm the current percentage of voting rights held in treasury (6.06%) to assess potential dilution or voting power implications.
- Note that the VWAP of 1,509.04p reflects the market price during the execution window on September 11, 2025.
- Review the referenced Form 20-F (2024) and Q2 2025 results for broader context on the Company's financial health and risk factors.